Devlin Jodi's Form 4 filing
TriSalus Life Sciences, Inc. (TLSI) · filed Mar 20, 2026
- Accession no.
- 0001628280-26-020190
- Filed
- Mar 20, 2026
- Trade date
- Mar 11-16, 2026
- Filing delay
- 9 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions. Open-market sales total $13.2K. It was filed 9 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Devlin JodiCIK 0001992151 | Officer (Chief of Clinical Operations) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 11, 2026 | Common Stock | SSaleDisposed | −1,162 | $4.13 | −$4,799.06 | 99,409 | Direct | |
| Mar 12, 2026 | Common Stock | SSaleDisposed | −1,772 | $4.09 | −$7,247.48 | 97,637 | Direct | |
| Mar 16, 2026 | Common Stock | SSaleDisposed | −273 | $4.12 | −$1,124.76 | 97,364 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.